Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 576-583

  Palumbo, Paul E ^{a,b,c,d,e,f,g,i}   Raskino, Claire ^{a,b,c,d,e,f,g}   Fiscus, Susan ^{a,b,c,d,e,f,g}   Pahwa, Savita ^{a,b,c,d,e,f,g}   Schutzbank, Ted ^{a,b,c,d,e,f,g,h}   Spector, Stephen A ^{a,b,c,d,e,f,g}   Baker, Carol J ^{a,b,c,d,e,f,g}   Englund, Janet A ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h SIEMENS AG   (Germany)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; ZIDOVUDINE;

EID: 0033372528     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314638     Document Type: Article

References (28)

1. 1. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-5.
2. 2. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997;336:1337-42.
3. 3. Kourtis AP, Ibegbu C, Nahmias AJ, et al. Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1996;335: 1431-6.
4. 4. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996;97:710-6.
5. + lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61.
6. 6. Englund JA, Baker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Pediatr Infect Dis J 1996;15:1025-36.
7. 7. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997;336: 1704-12.
8. 8. Kievits T, van Gemen B, van Strijp D, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35:273-86.
9. 9. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
10. 10. Crowder M, Hand D. Analysis of repeated measures. London: Chapman and Hall, 1990.
11. 11. Kalbfleisch MD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
12. 12. Freedman L, Graubard B, Schatzkin A. Statistical validation of intermediate eidpoints for chronic diseases. Stat Med 1992;11:167-78.
13. 13. Lin D, Fleming T, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997;16:1515-27.
14. 14. Mofenson LM, Korelitz J, Meyer WA 3rd, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997;175:1029-38.
15. 15. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996;335:1091-8.
16. 16. Antiretroviral therapy and medical management of pediatric HIV infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Pediatrics 1998;102:999-1085.
17. 17. McKinney R, Team PP. Pediatric ACTG Trial 300: clinical efficacy of ZDV/ 3TC vs. ddI vs. ZDV/ddI in symptomatic, HIV-infected children. In: Program and abstracts of the 35th annual meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: IDSA, 1997.
18. 18. Zheng NN, McQueen PW, Hurren L, et al. Changes in biologic phenotype of HIV during treatment of patients with didanosine. J Infect Dis 1996; 173:1092-6.
19. 19. De Gruttola V, Fleming T, Lin D, Coombs R. Perspective: validating surrogate markers - are we being naive? J Infect Dis 1997;175:237-46.
20. 20. Reichelderfer P, Coombs R. Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl 2):S19-24.
21. 21. Mildvan D, Landay A, De Gruttota V, Machado S, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997;24:764-74.
22. 22. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
23. + Lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118:674-80.
24. 24. De Gruttola V, Wulfsohn M, Fischl M, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993;6:359-65.
25. 25. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998;12:1823-32.
26. 26. Martel L, Valentine M, Ferguson L, Katz S, McKinney R. Virologic and CD4 response to treatment with nelfinavir in therapy experienced but protease inhibitor naive HIV-infected children. In: 5th Conference on Retrovirus and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
27. + T cells following ritonavir therapy in HIV-infected children with advanced disease. In: 5th Conference on Retrovirus and Opportunistic Infections; program and abstracts (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
28. 28. Marschner I, Collier A, Coombs R, et al. Use of changes in plasma levels of HIV-1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-7.